Hemab Therapeutics Holdings, Inc. quarterly report, Q1 FY2026

Business Context and Reporting Period

Hemab Therapeutics Holdings, Inc. (COAG) is a clinical-stage biotechnology company developing therapies for blood coagulation disorders. The reporting period covers the three months ended March 31, 2026. During this period, the company completed a corporate reorganization on March 30, 2026, moving its operations from Hemab ApS (Denmark) to a newly incorporated Delaware entity. The company has no approved products and has not generated any revenue from product sales.

Key Financial Metrics

Metric Q1 2026 Q1 2025
Revenue $0 $0
Net Loss $(22.7) million $(15.3) million
Operating Expenses $23.6 million $16.6 million
Research & Development $19.5 million $14.1 million
General & Administrative $4.2 million $2.5 million
Cash and Cash Equivalents (End of Period) $49.9 million $55.4 million
Marketable Securities $113.7 million $97.5 million
Total Liquidity (Cash + Securities) $163.5 million $152.9 million
Accumulated Deficit $(204.5) million $(133.3) million

Note: The filing does not provide a specific debt balance; liabilities consist primarily of accounts payable, accrued expenses, and operating lease liabilities totaling $13.7 million.

Material Changes vs. Prior Period

  • Increased Operating Loss: Net loss increased by $7.4 million (48%) compared to Q1 2025, driven primarily by higher operating expenses.
  • R&D Expense Growth: Research and development expenses rose by $5.4 million, attributed to a $2.3 million increase in personnel-related costs and a $2.2 million increase in discovery and other costs (consultancy resources).
  • G&A Expense Growth: General and administrative expenses increased by $1.7 million, driven by higher personnel costs, equity-based compensation, and professional service fees.
  • Cash Flow: Net cash used in operating activities increased to $21.6 million from $13.0 million in the prior year period.
  • Corporate Structure: The company transitioned from a Danish entity to a Delaware corporation, converting convertible preference shares to convertible preferred stock.

Guidance, Outlook, and Risks

Outlook and Liquidity: Management expects to continue incurring significant operating losses for the foreseeable future. As of March 31, 2026, the company held $163.5 million in cash and marketable securities. Management believes this, combined with net proceeds of approximately $317.2 million from an Initial Public Offering (IPO) completed on May 4, 2026 (a subsequent event), will fund operations into 2029.

Key Risks and Contingencies:

  • Internal Controls: The company identified material weaknesses in its internal control over financial reporting, specifically regarding the financial statement close process and information system controls.
  • Clinical Development: The company is heavily dependent on the success of its lead asset, sutacimig (Phase 1/2 for Glanzmann thrombasthenia and Factor VII deficiency), and HMB-002 (Phase 1/2 for Von Willebrand Disease). Serious adverse events of thrombosis have been identified in sutacimig development.
  • Capital Requirements: The company will require substantial additional funding to advance clinical trials, particularly the planned Phase 3 trial for sutacimig.
  • Regulatory Uncertainty: The FDA may require a randomized controlled trial for sutacimig approval rather than the planned single-arm trial, which could increase costs and delay timelines.

Investor Verification Checklist

  • Verify IPO Proceeds: Confirm the actual net proceeds received from the May 4, 2026 IPO and the updated cash balance post-IPO.
  • Internal Control Remediation: Review the specific steps and timeline management has established to remediate the identified material weaknesses in internal controls.
  • Clinical Trial Design: Monitor the outcome of the planned Type D meeting with the FDA regarding the Phase 3 trial design for sutacimig (single-arm vs. randomized).
  • Safety Profile: Track any new data regarding thrombotic events in the development of sutacimig and HMB-002.
  • Burn Rate: Assess the quarterly cash burn rate against the projected runway into 2029 to determine if additional financing will be needed sooner than anticipated.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.